JP7837345B2 - Tリンパ球結合アプタマー - Google Patents
Tリンパ球結合アプタマーInfo
- Publication number
- JP7837345B2 JP7837345B2 JP2023557840A JP2023557840A JP7837345B2 JP 7837345 B2 JP7837345 B2 JP 7837345B2 JP 2023557840 A JP2023557840 A JP 2023557840A JP 2023557840 A JP2023557840 A JP 2023557840A JP 7837345 B2 JP7837345 B2 JP 7837345B2
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- cancer
- cells
- cell
- aptamers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121080P | 2020-12-03 | 2020-12-03 | |
| US63/121,080 | 2020-12-03 | ||
| US202163257402P | 2021-10-19 | 2021-10-19 | |
| US63/257,402 | 2021-10-19 | ||
| PCT/IB2021/000849 WO2022118077A2 (en) | 2020-12-03 | 2021-12-03 | T-lymphocyte binding aptamers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023553193A JP2023553193A (ja) | 2023-12-20 |
| JP2023553193A5 JP2023553193A5 (cg-RX-API-DMAC7.html) | 2024-12-11 |
| JP7837345B2 true JP7837345B2 (ja) | 2026-03-30 |
Family
ID=80446452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557840A Active JP7837345B2 (ja) | 2020-12-03 | 2021-12-03 | Tリンパ球結合アプタマー |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12146140B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4256057A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7837345B2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303374A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022118077A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12146140B2 (en) | 2020-12-03 | 2024-11-19 | Aummune Ltd. | T-lymphocyte binding aptamers |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017143150A1 (en) | 2016-02-19 | 2017-08-24 | City Of Hope | Bi-specific aptamer |
| CN107129988A (zh) | 2016-02-29 | 2017-09-05 | 广西医科大学 | 一种特异性结合cd3的核酸适配体及其筛选方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2690441A1 (en) * | 2012-07-26 | 2014-01-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Method of determining a protein in a sample |
| WO2018017827A1 (en) | 2016-07-22 | 2018-01-25 | Fred Hutchinson Cancer Research Center | Bi-specific molecule for cell-specific notch inhibition and related methods and compositions |
| WO2019035763A1 (en) | 2017-08-16 | 2019-02-21 | Agency For Science, Technology And Research | APTAMERS FOR DETECTION OF ZIKA FLAVIVIRAL PROTEIN |
| US10584340B2 (en) * | 2017-09-29 | 2020-03-10 | University Of Florida Research Foundation, Inc. | Tau protein-binding DNA aptamers with capture/detection and therapeutic utilities in tauopathy-related neurodegenerative disorders |
| CN113423833B (zh) | 2018-09-28 | 2024-09-17 | 奥曼尼提纳米有限公司 | 用于选择功能性适体的方法和组合物 |
| US20230193286A1 (en) | 2020-05-20 | 2023-06-22 | Aummune Ltd. | Cytotoxic t-lymphocyte binding aptamers |
| US20230193285A1 (en) | 2020-05-20 | 2023-06-22 | Aummune Ltd. | Bispecific personalized aptamers |
| US12146140B2 (en) | 2020-12-03 | 2024-11-19 | Aummune Ltd. | T-lymphocyte binding aptamers |
-
2021
- 2021-12-03 US US17/542,046 patent/US12146140B2/en active Active
- 2021-12-03 EP EP21854938.4A patent/EP4256057A2/en active Pending
- 2021-12-03 IL IL303374A patent/IL303374A/en unknown
- 2021-12-03 JP JP2023557840A patent/JP7837345B2/ja active Active
- 2021-12-03 WO PCT/IB2021/000849 patent/WO2022118077A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017143150A1 (en) | 2016-02-19 | 2017-08-24 | City Of Hope | Bi-specific aptamer |
| CN107129988A (zh) | 2016-02-29 | 2017-09-05 | 广西医科大学 | 一种特异性结合cd3的核酸适配体及其筛选方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022118077A2 (en) | 2022-06-09 |
| EP4256057A2 (en) | 2023-10-11 |
| US20220186223A1 (en) | 2022-06-16 |
| US12146140B2 (en) | 2024-11-19 |
| IL303374A (en) | 2023-08-01 |
| WO2022118077A3 (en) | 2022-09-29 |
| JP2023553193A (ja) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102657218B1 (ko) | Igf-1r 억제용 p-에톡시 핵산 | |
| CN109072240A (zh) | 使用piRNA诊断和治疗癌症的组合物和方法 | |
| WO2018067991A1 (en) | Modulation of novel immune checkpoint targets | |
| JP2014500024A (ja) | 腫瘍細胞溶解を媒介する二重特異性アプタマー | |
| TW201130495A (en) | Organic compositions to treat HSF1-related diseases | |
| KR20220008383A (ko) | 베타-ENaC-관련 질환을 치료하기 위한 유기 조성물 | |
| TW201103983A (en) | Aptamer against chymase and use thereof | |
| JP2020114835A (ja) | 療法用ナノ粒子および関連する組成物、方法、およびシステム | |
| CN111447922A (zh) | 用于igf-1r抑制的p-乙氧基核酸 | |
| JP2019534708A (ja) | Pd−1特異的アプタマー | |
| JP2023526328A (ja) | siRNAを使用してPRDM2/RIZタンパク質の発現を調節するがん治療 | |
| CN121532196A (zh) | 半乳糖凝集素-1作为免疫检查点在制备肿瘤免疫治疗药物中的应用以及该药物 | |
| JP7753256B2 (ja) | 二重特異性個別化アプタマー | |
| US20230193286A1 (en) | Cytotoxic t-lymphocyte binding aptamers | |
| JP2023553193A (ja) | Tリンパ球結合アプタマー | |
| CN111542607A (zh) | 针对adamts5的适配体及其应用 | |
| JPWO2015163458A1 (ja) | オートタキシンに結合しオートタキシンの生理活性を阻害するアプタマー及びその利用 | |
| KR20260046091A (ko) | 프로그램된 사멸 리간드 수용체(pd-l1) 발현을 위한 조성물 및 방법 | |
| CN113508175B (zh) | 用于治疗癌症的组合物和方法 | |
| CN117280033A (zh) | T-淋巴细胞结合适体 | |
| WO2024107993A1 (en) | Stat3 targeting oligonucleotides and uses thereof | |
| CN112912501B (zh) | 寡核苷酸分子及其在肿瘤治疗中的应用 | |
| JP2023553193A5 (cg-RX-API-DMAC7.html) | ||
| EP3737393A1 (en) | Mirna modulation of t cell signaling and uses thereof | |
| JPWO2015147290A1 (ja) | オートタキシンに結合しオートタキシンの生理活性を阻害するアプタマー及びその利用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241203 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241203 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260224 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260302 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260317 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7837345 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |